ERYP News and Press, Erytech Pharma S.A. From 05/07/20

Erytech Pharma (NASDAQ: ERYP ): Q1 Cash and equivalents of €58.6M More news on: ERYTECH Pharma S.A., Earnings news and commentary, Healthcare stocks news, , Read more ...

Conference call and webcast on Thursday, May 7 at 2:30 pm CET/8:30 am ET TRYbeCA-1 Phase 3 Trial: More than 75% of the planned ~ 500 patients enrolled Fast-Drack designation granted by U.S. FDA Trial to continue as planned after third independent safety review Interim superi...

LYON, France and CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced it will be part of EVIDENC...

Erytech Pharma Gets FDA Boost for Eryaspase Erytech Pharma SA (ERYP) announced that the FDA has granted Fast Track status to its lead drug candidate Eryaspase. The drug candidate is being evaluated as the second line treatment for metastatic pancreatic cancer. With Fast Track designation...

LYON, France, April 30, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its 2020...

Ultra-thinly traded micro cap ERYTECH Pharma S.A. ( ERYP +37.0% ) is up out of the gate, albeit on turnover of only 13K shares, on the heels of the FDA's granting of Fast Track status for lead drug eryaspase for the second-line treatment of metastatic pancreatic cancer. More news on: E...

Fast Track designation for eryaspase underscores the urgent need for potential new treatment options for patients with second line metastatic pancreatic cancer LYON, France and CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a...

More than 75% of the planned ~ 500 patients enrolled in the trial Trial to continue as planned after third safety review by independent data monitoring committee Interim superiority analysis expected around year-end; final analysis in second half of 2021 LYON, France, April...

LYON, France, April 06, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) &a...

LYON, France and CAMBRIDGE, Mass., March 19, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it had fi...